TY - JOUR
T1 - Escherichia coli O157:H7 Hemorrhagic Colitis
AU - Tarr, Phillip I.
AU - Neill, Marguerite A.
AU - Christie, Dennis L.
AU - Anderson, Donald E.
PY - 1988/6/23
Y1 - 1988/6/23
N2 - To the Editor: Like Carter et al.1 in their article and Sack in his editorial2 in the December 10 issue, we too are concerned that antibiotic treatment of hemorrhagic colitis may increase the risk of hemolytic uremic syndrome. Escherichia coli O157:H7, an organism that produces Shiga-like toxins (also called verocytotoxins), is the enteric pathogen most commonly isolated from patients with hemolytic uremic syndrome.3 4 5 6 7 Current concepts of pathogenesis focus on the role of these toxins in systemic cellular injury that results in the microangiopathy and nephropathy of hemolytic uremic syndrome.8 Antibiotics could influence this pathophysiologic sequence by two mechanisms. The first,.
AB - To the Editor: Like Carter et al.1 in their article and Sack in his editorial2 in the December 10 issue, we too are concerned that antibiotic treatment of hemorrhagic colitis may increase the risk of hemolytic uremic syndrome. Escherichia coli O157:H7, an organism that produces Shiga-like toxins (also called verocytotoxins), is the enteric pathogen most commonly isolated from patients with hemolytic uremic syndrome.3 4 5 6 7 Current concepts of pathogenesis focus on the role of these toxins in systemic cellular injury that results in the microangiopathy and nephropathy of hemolytic uremic syndrome.8 Antibiotics could influence this pathophysiologic sequence by two mechanisms. The first,.
UR - https://www.scopus.com/pages/publications/0023932003
U2 - 10.1056/NEJM198806233182515
DO - 10.1056/NEJM198806233182515
M3 - Letter
C2 - 3287166
AN - SCOPUS:0023932003
SN - 0028-4793
VL - 318
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 25
ER -